JP2021518415A5 - - Google Patents
Info
- Publication number
- JP2021518415A5 JP2021518415A5 JP2020550856A JP2020550856A JP2021518415A5 JP 2021518415 A5 JP2021518415 A5 JP 2021518415A5 JP 2020550856 A JP2020550856 A JP 2020550856A JP 2020550856 A JP2020550856 A JP 2020550856A JP 2021518415 A5 JP2021518415 A5 JP 2021518415A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable sequence
- seq
- antibody
- light chain
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023196493A JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647546P | 2018-03-23 | 2018-03-23 | |
| US62/647,546 | 2018-03-23 | ||
| PCT/US2019/022444 WO2019182888A1 (en) | 2018-03-23 | 2019-03-15 | Human pd-l2 antibodies and methods of use therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196493A Division JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518415A JP2021518415A (ja) | 2021-08-02 |
| JPWO2019182888A5 JPWO2019182888A5 (https=) | 2022-02-09 |
| JP2021518415A5 true JP2021518415A5 (https=) | 2022-02-09 |
| JP7390301B2 JP7390301B2 (ja) | 2023-12-01 |
Family
ID=67987459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550856A Active JP7390301B2 (ja) | 2018-03-23 | 2019-03-15 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
| JP2023196493A Active JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196493A Active JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11976128B2 (https=) |
| EP (1) | EP3768298A4 (https=) |
| JP (2) | JP7390301B2 (https=) |
| CN (2) | CN119101158A (https=) |
| AU (2) | AU2019239620B2 (https=) |
| CA (1) | CA3092695A1 (https=) |
| WO (1) | WO2019182888A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075097A1 (en) | 2017-10-11 | 2019-04-18 | Board Of Regents, The University Of Texas System | PD-L1 HUMAN ANTIBODIES AND METHODS OF USE |
| CN119101158A (zh) * | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| EP3768726B1 (en) | 2018-03-23 | 2024-10-30 | Board of Regents, The University of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| WO2019182867A1 (en) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| CN120693348A (zh) * | 2023-02-04 | 2025-09-23 | 玛布树生物股份公司 | 人抗pd-l2抗体及其用途 |
| JP2026506269A (ja) * | 2023-09-17 | 2026-02-24 | ジー イェン バイオメディカル カンパニー リミテッド | 組換え抗体及びその用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20040131613A1 (en) | 2003-01-08 | 2004-07-08 | Watkins Jeffry D. | TNF-alpha binding molecules |
| JP4999158B2 (ja) | 2003-05-21 | 2012-08-15 | メダレツクス・インコーポレーテツド | 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| EP1768999B1 (en) * | 2004-06-30 | 2013-06-19 | Mayo Foundation For Medical Education And Research | sHIgM12 antibody useful to treat multiple sclerosis |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| JP5576610B2 (ja) | 2006-02-20 | 2014-08-20 | フィロジカ リミテッド | ペプチド構造のライブラリーの構築およびスクリーニング方法 |
| CL2008001071A1 (es) | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| TW200927761A (en) * | 2007-09-26 | 2009-07-01 | U3 Pharma Ag | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| US9044457B2 (en) * | 2010-06-16 | 2015-06-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-DR4 agonist antibodies |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| JP6403166B2 (ja) * | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法 |
| KR20220062143A (ko) | 2014-01-06 | 2022-05-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
| WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| AU2016229201B2 (en) | 2015-03-06 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | Anti-LILRB antibodies and their use in detecting and treating cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CA2995502A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| KR20240133761A (ko) | 2015-10-19 | 2024-09-04 | 다케다 파머수티컬 컴패니 리미티드 | 절단된 고분자량 키니노겐의 검출을 위한 면역검정법 |
| EP3390454B1 (en) | 2015-12-17 | 2026-02-04 | University of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| KR20180130541A (ko) * | 2016-03-29 | 2018-12-07 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법 |
| CN116217731B (zh) | 2016-04-22 | 2025-12-30 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| WO2017200796A1 (en) | 2016-05-17 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Engineered pd-1 variants |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN106957823A (zh) | 2016-12-28 | 2017-07-18 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l2蛋白单克隆抗体及其用途 |
| WO2019075097A1 (en) | 2017-10-11 | 2019-04-18 | Board Of Regents, The University Of Texas System | PD-L1 HUMAN ANTIBODIES AND METHODS OF USE |
| CN119101158A (zh) * | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| EP3768726B1 (en) | 2018-03-23 | 2024-10-30 | Board of Regents, The University of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| WO2019182867A1 (en) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
-
2019
- 2019-03-15 CN CN202411090419.0A patent/CN119101158A/zh active Pending
- 2019-03-15 JP JP2020550856A patent/JP7390301B2/ja active Active
- 2019-03-15 AU AU2019239620A patent/AU2019239620B2/en active Active
- 2019-03-15 US US17/040,269 patent/US11976128B2/en active Active
- 2019-03-15 WO PCT/US2019/022444 patent/WO2019182888A1/en not_active Ceased
- 2019-03-15 CA CA3092695A patent/CA3092695A1/en active Pending
- 2019-03-15 EP EP19771524.6A patent/EP3768298A4/en active Pending
- 2019-03-15 CN CN201980021120.0A patent/CN111902156B/zh active Active
-
2023
- 2023-11-20 JP JP2023196493A patent/JP7624497B2/ja active Active
-
2024
- 2024-03-20 US US18/611,087 patent/US12428489B2/en active Active
-
2025
- 2025-09-10 US US19/324,749 patent/US20260008866A1/en active Pending
-
2026
- 2026-04-07 AU AU2026202554A patent/AU2026202554A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518415A5 (https=) | ||
| CN113748133B (zh) | 肿瘤治疗剂及其应用 | |
| JP2021518390A5 (https=) | ||
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| JP2022515318A (ja) | 抗体及びその用途 | |
| CN108084265B (zh) | 特异性结合人的5t4抗原的全人源单域抗体及其应用 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP7836033B2 (ja) | Ｇｐｒｃ５ｄ抗体及びその応用 | |
| JP2021528047A5 (https=) | ||
| JP2018520334A5 (https=) | ||
| CN107001452A (zh) | 用于治疗癌症的抗ck8抗体 | |
| JP2018513141A5 (https=) | ||
| JPWO2019217145A5 (https=) | ||
| CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| JPWO2019182888A5 (https=) | ||
| CN116284407A (zh) | 一种抗gucy2c抗体或其抗原结合片段及其用途 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JPWO2019182867A5 (https=) | ||
| JP2020515286A5 (https=) | ||
| CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
| KR102614063B1 (ko) | 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체 | |
| JPWO2020163325A5 (https=) | ||
| Yu et al. | RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer |